Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine?
Current Opinion in Nephrology & Hypertension1999Vol. 8(6), pp. 669–674
Citations Over TimeTop 14% of 1999 papers
Abstract
Cyclosporine and tacrolimus are potent inhibitors of the calcineurin-dependent cytokine synthesis in activated lymphocytes. In renal transplant patients tacrolimus is more powerful in preventing severe and refractory rejections, even when compared with the new cyclosporine microemulsion formulation. Both drugs are equally nephrotoxic, but tacrolimus induces less hypertension and less pronounced hyperlipidaemia. Especially in some categories of patients, a higher incidence of de-novo diabetes mellitus is seen with tacrolimus therapy.
Related Papers
- → Ciclosporin versus tacrolimus for HCV transplant recipients(2011)6 cited
- → Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine?(1999)32 cited
- → Strategies to minimize nephrotoxicity associated to calcineurin inhibitors(1999)
- → Systematic literature review, meta-analysis and indirect treatment comparison of prolonged-release tacrolimus relative to ciclosporin and immediate-release tacrolimus as the primary immunosuppressive regimen in Liver Transplant Recipients(2015)
- Tacrolimus in the prevention of graft rejection: new indication. Helpful alternative to ciclosporin.(1998)